More than 5,000 women in Thailand die every year from cervical cancer [1], according to the 2019 report from the HPV Information Centre. 70% of these cancers are caused by just two human papillomavirus (HPV) strains: HPV16 and HPV18. Both of these strains are now vaccine-preventable, but the HPV Information Centre estimates that it will take decades […]
Time to review the gold standard for cervical cancer screening Read More »
The Teal project brought together the Roche Team, Christian Action, University of Hong Kong, Karen Leung Foundation and Central Health to offer Co-testing for HPV to hundreds of under privileged women in the busy city of Hong Kong. Their efforts constituted a fight against one of the most common but preventable cancers affecting women.
Pap in the City: a journey to co-testing for HPV in Hong Kong Read More »
Angiogenic biomarkers have been shown to improve the clinical management of preeclampsia. Preeclampsia is a placental disease caused by trophoblast dysfunction. The angiogenic factors placental growth factor (PlGF) and soluble fms-like tyrosine kinase 1 (sFlt-1), all originating at least in part from the trophoblast, are biomarkers with predictive potential for preeclampsia and related adverse outcomes. The 60-minute webinar focuses on how
The roles of biomarkers in preeclampsia management Read More »
HPV DNA testing is shown to be significantly more effective compared to pap smear/cytology for cervical cancer screening. In this webinar, you will learn how to implement HPV DNA testing as a primary screening tool for cervical cancer. How to address multidisciplinary challenges during the transition phase from pap smear/cytology to HPV DNA testing? What are the considerations
How to implement HPV DNA testing as a primary screening tool? Read More »
Full presentation by Prof Liona Poon delivered to clinicians at the 2018 NIPT Forum Asia held in Bangkok, Thailand.
Updated evidence and implementation models of cfDNA testing Read More »
Prenatal visits are generally happy occasions, but many women still experience some anxiety as every pregnancy comes with a risk of chromosomal abnormalities. Fortunately, advances in non-invasive prenatal test technologies (NIPT) make the testing process more convenient and reliable than ever before. The Rise of cfDNA Analysis for NIPT Since its introduction in the 1990s,
The evolution of non-invasive prenatal test technologies Read More »
Subscribe to Lab Insights latest news and update
Join over 3,000 HCPs receiving insights in their inbox.
